Global E-Health Forum - Hamburg 2011

11 - 13 October 2011, Hamburg, Germany.
Improving the quality of healthcare, increasing the efficiency of the systems and ensuring patient empowerment - these are the common goals worldwide when discussing the necessary transformation of the systems in order to guarantee a sustainable healthcare delivery in the future. The Global E-Health Forum - Hamburg 2011 will represent major stakeholders involved in designing personalized healthcare.

"E-Health is increasingly seen as a key enabler for this transformation," so Ljubisav Matejevic, founder and honorary chairman of the Global E-Health Forum. "And as a key enabler for the evolution process towards personalized healthcare. Healthcare that is proactive, instead of reactive, gives the patients the opportunity and the responsibility to become more involved in their own health. The ultimate goal will be to shape preventive and diagnostic care to match each person's unique characteristics."

The initiators of the Global E-Health Forum - Hamburg Chamber of Commerce, IBM and ICC - have developed this platform to discuss e-health strategies, best practices and new services/patient-centric approaches in a global context. While the main target groups consist of CEOs, CIOs and CFOs of hospitals and clinics, the comprehensive program will also attract representatives from governmental bodies, health insurance organizations, service providers, influencers from hospital and health management associations as well as representatives from universities/research institutes. Canada supports the Global E-Health Forum - Hamburg 2011 as partner country.

The first two conference days will feature speakers from all over the globe:

  • Richard C. Alvarez, President and Chief Executive Officer of Canada Health Infoway, with "Transforming Healthcare in Canada through E-Health"
  • Prof. WEN Ze Huai, (M. D.), Key Unit of Methodology in Clinical Research, Guangdong Traditional Chinese Medicine International Clinical Research Center, Research Center Guangdong Academy of Chinese Medical Sciences, with "Designing Personalized Healthcare for Integrated Medicine by Using Information Technology"
  • Dr. Eric M. Liederman, Director of Medical Informatics, The 45 Permanente Medical Group (USA), with "Balancing Privacy Protection with Patient Care"
  • Prof. Dr. Roland Eils, Division Head "Theoretical Bioinformatics", German Cancer Research Center (DKFZ) and Manuela Mueller-Gerndt, Healthcare Leader, IMT Germany, Smarter Healthcare, IBM Deutschland GmbH with "Oncology as a Key Driver for Cancer Research and Individualized Medicine"
  • Chai Chuah, National Director, National Health Board Business Unit, New Zealand Ministry of Health, with "Sustainable Personalized Healthcare - Challenges and Opportunities"

Their strategy presentations and case studies will be complemented by discussion forums, workshops and an exhibition of solution providers. During the evening reception at the U.S. Consulate General on October 11, there will be manifold opportunity of knowledge and experience exchange as well as networking. The third day is dedicated to various breakout sessions and guided tours at different locations (among others hospitals) targeting the individual information needs of special interest groups. The third day is dedicated to guided tours of different hospitals and clinics in Hamburg, three of them being Asklepios clinics. The Asklepios Hospital Group renewed its cooperation partnership with the Global E-Health Forum.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...